Advertisement
FATE vs SANA
Which Stock Would AI Choose? Fate Therapeutics (FATE) vs. Sana Biotechnology (SANA) Stock Comparison
Key Takeaways
- Two clinical-stage cell-therapy names with very different market positioning: FATE focuses on "off-the-shelf" CAR T-cell and NK-cell therapies, while SANA centers on its hypoimmune platform for diabetes and blood cancers.
- Contrasting momentum: FATE has delivered a strong year-to-date advance, while SANA has traded lower over the same stretch despite a larger market capitalization.
- Both remain pre-revenue: Each company burns cash to fund early-stage pipelines, making clinical catalysts and capital runway central to relative performance.
- Divergent catalyst profiles: FATE's story is anchored by its FT819 program in lupus nephritis; SANA's is anchored by its SC451 program for type 1 diabetes and in vivo CAR T work.
- For more detail on each company's developments and daily price action, explore FATE Major News, FATE Today's Price Move, SANA Major News, and SANA Today's Price Move.
- To see how automated systems are interpreting current conditions across thousands of tickers, visit Trending AI Robots.
Introduction
Fate Therapeutics and Sana Biotechnology both sit at the frontier of engineered cell therapy, yet they are attacking different diseases with different technological approaches. This comparison is relevant to investors and traders evaluating speculative, early-stage biotechnology, where clinical data and balance-sheet durability often drive share prices more than near-term revenue. FATE represents a smaller-cap, momentum-oriented story built on induced pluripotent stem cell (iPSC)-derived, off-the-shelf cell therapies. SANA is a larger-cap name pursuing immune-evasive cell therapies led by a type 1 diabetes program. Because neither company generates meaningful product revenue, relative performance hinges on clinical catalysts, sentiment, and financing capacity.
FATE Overview and Recent Performance
Fate Therapeutics is a clinical-stage biopharmaceutical company developing programmed cellular immunotherapies for cancer and autoimmune disease. Its iPSC (induced pluripotent stem cell) platform is designed to produce uniform, inventory-ready CAR T-cell and NK-cell therapies that avoid the manufacturing limits of patient-derived approaches. In recent weeks, investor attention has centered on FT819, an off-the-shelf CD19-targeting CAR T-cell candidate now in a Phase 2 trial (RECLAIM-LN) for lupus nephritis, with early dosing conducted in an outpatient setting. The company also secured grant funding to support that study.
The stock has shown notable relative strength, posting a triple-digit year-to-date gain and trading near the upper portion of its 52-week range, though it remains a low-single-digit priced, roughly $250 million market-cap name. Analyst coverage leans constructive, with several firms reiterating Buy ratings and price targets well above recent trading levels. Sentiment has been shaped by early clinical signals in lupus, a growing cash position supporting an operating runway extending into 2028, and broader investor appetite for autoimmune-focused cell therapy.
SANA Overview and Recent Performance
Sana Biotechnology develops engineered cells as medicines using its hypoimmune (HIP) platform, which aims to create cells that evade immune detection and can be transplanted without immunosuppression. Its pipeline spans type 1 diabetes, B-cell-mediated autoimmune diseases, and blood cancers. The lead program, SC451, is a stem-cell-derived pancreatic islet cell therapy for type 1 diabetes, with regulatory filings and Phase 1 testing targeted in the near term. The company has also published long-term data in the New England Journal of Medicine on its UP421 islet cell therapy, supporting durability without immunosuppression.
Despite these scientific milestones, SANA's stock has declined over the year-to-date period and trades toward the lower end of its 52-week range, even as its market capitalization remains well above FATE's. Recent months have brought a Mayo Clinic collaboration, an at-the-market (ATM) equity raise, and a narrowing adjusted net loss, reflecting tighter cost discipline. However, ongoing cash burn and reliance on external financing continue to weigh on sentiment and contribute to elevated share-price volatility.
Trending AI Robots
Tickeron maintains a library of hundreds of AI trading bots that monitor and trade thousands of different tickers across the market. Because conditions shift constantly, only a curated subset of the most suitable bots earns a place in the Trending AI Robots section. These bots span a wide range of trading styles, strategies, timeframes, performance records, and statistical profiles, and each manages its own set of tickers. This selection is designed to help traders identify automated approaches aligned with the current market environment rather than static, one-size-fits-all signals. For investors comparing names such as FATE and SANA, reviewing the Trending AI Robots page can offer an additional, data-driven perspective on momentum and positioning.
Head-to-Head Comparison
The two companies diverge sharply across several dimensions. Business model: FATE is built around a single iPSC manufacturing platform producing off-the-shelf cell therapies, while SANA spans multiple platforms, including hypoimmune-modified cells and in vivo CAR T delivery. Growth drivers: FATE's near-term narrative is concentrated in FT819 for lupus nephritis, whereas SANA's hinges on type 1 diabetes (SC451, UP421) plus earlier-stage oncology programs.
Momentum and sentiment: FATE has outperformed recently, benefiting from clinical progress and analyst support, while SANA has lagged despite meaningful scientific publications. Risk factors: both face binary clinical outcomes and persistent cash burn, but SANA's larger market cap and recent equity issuance highlight a heavier financing footprint. Sector exposure: both are biotechnology names, though FATE skews toward autoimmune disease and SANA toward regenerative medicine and diabetes. Investors weighing relative performance should note that FATE's smaller capitalization amplifies upside and downside moves, while SANA's broader pipeline may diversify single-asset risk.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor FATE in the current environment. The stock has demonstrated stronger trend consistency and relative performance over recent months, supported by advancing clinical catalysts and a favorable analyst posture. SANA's platform remains scientifically compelling, but its weaker price momentum and heavier reliance on financing currently weigh on its relative positioning. This assessment is probabilistic rather than definitive: it reflects momentum and stability rather than a judgment on either company's long-term therapeutic potential, and conditions could shift quickly with new clinical data or financing developments.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a StrongBuy and SANA is a Hold.
FATE in +3.98% Uptrend, advancing for three consecutive days on November 04, 2026
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where FATE advanced for three days, in 214 of 246 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator entered the oversold zone -- be on the watch for FATE's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
FATE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on FATE as a result. In 85 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for FATE turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 49 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where FATE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for FATE entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.433) is normal, around the industry mean (3.498). P/E Ratio (-1.748) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (45.045) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. FATE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. FATE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
SANA's RSI Oscillator recovers from oversold territory
The RSI Indicator for SANA moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 43 similar instances when the indicator left oversold territory. In 37 of the 43 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The Moving Average Convergence Divergence (MACD) for SANA just turned positive on October 26, 2026. Looking at past instances where SANA's MACD turned positive, the stock continued to rise in 33 of 41 cases over the following month. The odds of a continued upward trend are 80%.
Following a +5.34% 3-day Advance, the price is estimated to grow further. Considering data from situations where SANA advanced for three days, in 186 of 235 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on SANA as a result. In 68 of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SANA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
SANA broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SANA entered a downward trend on October 28, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 17 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.590) is normal, around the industry mean (3.498). P/E Ratio (-3.160) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. SANA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SANA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
FATE | ||
|---|---|---|
OUTLOOK RATING 1..100 | 66 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 98 | |
PRICE GROWTH RATING 1..100 | 62 | |
P/E GROWTH RATING 1..100 | 13 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| FATE | SANA | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 84% | 1 day ago 86% |
| Stochastic ODDS (%) | 1 day ago 83% | 1 day ago 86% |
| Momentum ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| MACD ODDS (%) | 1 day ago 90% | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 90% | 1 day ago 90% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 89% |
| Advances ODDS (%) | 9 days ago 87% | 4 days ago 79% |
| Declines ODDS (%) | 1 day ago 90% | 1 day ago 89% |
| BollingerBands ODDS (%) | 1 day ago 85% | 1 day ago 90% |
| Aroon ODDS (%) | 1 day ago 90% | 1 day ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
FATE’s FA Score shows that 1 FA rating(s) are green while SANA’s FA Score has 1 green FA rating(s).
- FATE’s FA Score: 1 green, 4 red.
- SANA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
FATE’s TA Score shows that 4 TA indicator(s) are bullish while SANA’s TA Score has 4 bullish TA indicator(s).
- FATE’s TA Score: 4 bullish, 4 bearish.
- SANA’s TA Score: 4 bullish, 4 bearish.
Price Growth
FATE (@Biotechnology) experienced а -23.21% price change this week, while SANA (@Biotechnology) price change was -10.55% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +11.66%. For the same industry, the average monthly price growth was +1.65%, and the average quarterly price growth was -13.40%.
Reported Earning Dates
FATE is expected to report earnings on Mar 01, 2027.
SANA is expected to report earnings on Mar 23, 2027.
Industries' Descriptions
@Biotechnology (+11.66% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
SANA and
Correlation & Price change
A.I.dvisor indicates that over the last year, SANA has been loosely correlated with EDIT. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if SANA jumps, then EDIT could also see price increases.
| Ticker / NAME | Correlation To SANA | 1D Price Change % | ||
|---|---|---|---|---|
| SANA | 100% | -5.76% | ||
| EDIT - SANA | 59% Loosely correlated | -4.99% | ||
| CRSP - SANA | 58% Loosely correlated | +1.33% | ||
| RCKT - SANA | 56% Loosely correlated | +1.22% | ||
| BEAM - SANA | 56% Loosely correlated | +2.62% | ||
| RXRX - SANA | 55% Loosely correlated | +1.13% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| AIYY | 7.29 | 0.14 | +1.96% |
| YieldMax AI Option Income Strategy ETF (AIYY) | |||
| SCHK | 36.54 | 0.47 | +1.30% |
| Schwab 1000 Index ETF (SCHK) | |||
| ESMV | 32.56 | 0.33 | +1.02% |
| iShares ESG Optimized MSCI USA Min Vol Factor ETF (ESMV) | |||
| UFEB | 39.75 | 0.26 | +0.66% |
| Innovator U.S. Equity Ultra Buffer ETF - February (UFEB) | |||
| WWJD | 39.84 | 0.07 | +0.18% |
| Inspire International ETF (WWJD) | |||